MX338063B - Molecula de union especifica al rsv. - Google Patents

Molecula de union especifica al rsv.

Info

Publication number
MX338063B
MX338063B MX2012004086A MX2012004086A MX338063B MX 338063 B MX338063 B MX 338063B MX 2012004086 A MX2012004086 A MX 2012004086A MX 2012004086 A MX2012004086 A MX 2012004086A MX 338063 B MX338063 B MX 338063B
Authority
MX
Mexico
Prior art keywords
rsv
specific binding
binding molecule
antibody
producing
Prior art date
Application number
MX2012004086A
Other languages
English (en)
Other versions
MX2012004086A (es
Inventor
Tim Beaumont
Adrianus Quirinus Bakker
Etsuko Yasuda
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2012004086A publication Critical patent/MX2012004086A/es
Publication of MX338063B publication Critical patent/MX338063B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos y equivalentes funcionales del mismo que son capaces de enlazar o unirse específicamente al RSV. También se proporcionan las secuencias de ácido nucleico que codifican dicho anticuerpo, así como las células que producen el anticuerpo y métodos para producir dicho anticuerpo.
MX2012004086A 2009-10-06 2009-10-06 Molecula de union especifica al rsv. MX338063B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2009/050599 WO2011043643A1 (en) 2009-10-06 2009-10-06 Rsv-specific binding molecule

Publications (2)

Publication Number Publication Date
MX2012004086A MX2012004086A (es) 2012-09-12
MX338063B true MX338063B (es) 2016-04-01

Family

ID=42153917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004086A MX338063B (es) 2009-10-06 2009-10-06 Molecula de union especifica al rsv.

Country Status (14)

Country Link
EP (1) EP2486053B1 (es)
JP (1) JP5734988B2 (es)
KR (1) KR101789343B1 (es)
CN (1) CN102712692B (es)
AU (1) AU2009353693B2 (es)
BR (1) BR112012008173B1 (es)
CA (1) CA2776249C (es)
ES (1) ES2621458T3 (es)
IL (1) IL219021A (es)
MX (1) MX338063B (es)
NZ (1) NZ599148A (es)
RU (2) RU2540020C2 (es)
WO (1) WO2011043643A1 (es)
ZA (1) ZA201202502B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
BRPI0619579B8 (pt) 2005-12-09 2022-01-25 Academisch Medisch Centrum Bij De Univ Van Amsterdam Métodos para aumentar a expectativa de vida replicativa e/ou estabilidade de uma célula produtora de anticorpo, para expressar um gene de uma célula b codificando a cadeia pesada de ig e/ou cadeia leve de ig, para produzir linhagem de células b, para obter anticorpos, e, método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse
IN2014DN10515A (es) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
DK2646466T3 (en) 2010-12-02 2017-06-06 Aimm Therapeutics Bv METHODS AND METHODS FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
WO2013095091A2 (en) 2011-11-17 2013-06-27 Aimm Therapeutics B.V. Rsv g protein specific antibodies
BR112014013081A2 (pt) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
JP6226752B2 (ja) 2012-02-09 2017-11-08 中外製薬株式会社 抗体のＦｃ領域改変体
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
US10016496B2 (en) 2013-02-01 2018-07-10 Medimmune, Llc Respiratory syncytial virus F protein epitopes
CN105473604B (zh) 2013-03-13 2021-01-22 美国政府(由卫生和人类服务部的部长所代表) 融合前rsv f蛋白和其用途
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CA2906960C (en) * 2013-03-15 2021-07-20 Xiamen University Epitope of rsv fusion protein and antibody recognizing the epitope
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
CA2933200C (en) * 2014-01-15 2025-05-06 Medimmune Limited RSV-SPECIFIC ANTIBODIES AND THEIR FUNCTIONAL PARTS
EP3099709B1 (en) 2014-01-31 2019-12-25 AIMM Therapeutics B.V. Means and methods for producing stable antibodies
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
CN106496324B (zh) * 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
MY205060A (en) 2015-12-23 2024-09-30 Pfizer Rsv f protein mutants
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
RU2713340C1 (ru) * 2018-12-28 2020-02-04 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам респираторно-синцитиального вируса
KR20250054810A (ko) 2022-09-29 2025-04-23 화이자 인코포레이티드 Rsv f 단백질 삼량체를 포함하는 면역원성 조성물
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
EP4608441A1 (en) 2022-10-27 2025-09-03 Pfizer Inc. Immunogenic compositions against influenza and rsv
EP4630049A1 (en) 2022-12-11 2025-10-15 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026038177A1 (en) 2024-08-16 2026-02-19 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
AU2003295411A1 (en) * 2002-11-07 2004-06-03 Celltech R & D Human monoclonal antibodies to heparanase
WO2005079479A2 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2185590A2 (en) * 2007-09-07 2010-05-19 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
WO2009114815A1 (en) * 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs

Also Published As

Publication number Publication date
CN102712692B (zh) 2014-12-31
CA2776249C (en) 2021-01-19
JP5734988B2 (ja) 2015-06-17
JP2013506431A (ja) 2013-02-28
MX2012004086A (es) 2012-09-12
ZA201202502B (en) 2014-06-25
IL219021A0 (en) 2012-06-28
EP2486053A1 (en) 2012-08-15
RU2014151788A3 (es) 2018-07-09
RU2012118636A (ru) 2013-11-20
EP2486053B1 (en) 2017-01-18
CA2776249A1 (en) 2011-04-14
AU2009353693A1 (en) 2012-04-19
RU2540020C2 (ru) 2015-01-27
KR20120084755A (ko) 2012-07-30
CN102712692A (zh) 2012-10-03
WO2011043643A1 (en) 2011-04-14
BR112012008173A2 (pt) 2017-10-10
AU2009353693B2 (en) 2016-07-21
KR101789343B1 (ko) 2017-10-23
ES2621458T3 (es) 2017-07-04
IL219021A (en) 2016-11-30
NZ599148A (en) 2014-08-29
BR112012008173B1 (pt) 2021-12-07
RU2014151788A (ru) 2016-07-10

Similar Documents

Publication Publication Date Title
MX338063B (es) Molecula de union especifica al rsv.
MX350375B (es) Moleculas de union especificas de virus sincitial respiratorio y medios para producirlas.
WO2010145792A8 (en) Bispecific antigen binding proteins
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
SG179196A1 (en) Coiled coil and/or tether containing protein complexes and uses thereof
MX2010008099A (es) Anticuerpos y angiopoyetina-2 estabilizados y sus usos.
EA201171148A1 (ru) Антитело-антагонист, специфичное для гетеродимера альфа-4-бета-7
PH12012501157A1 (en) Anti-her3 antibodies and uses thereof
IL217827A0 (en) Muc1 antibodies, nucleic acids encoding the same and methods for producing the same
HK1212711A1 (zh) Bcma抗原結合蛋白
WO2009112245A9 (en) Antibody against the csf-1 r
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2010127304A3 (en) Sequencing methods
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
SG178886A1 (en) Humanized anti-cdcp1 antibodies
WO2012109373A3 (en) Treatment of osteoarthritis and pain
PH12013502205A1 (en) Antibodies to il-6 and their uses
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
WO2009130459A3 (en) Epitopes of il-17a and il-17f and antibodies specific thereto
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
WO2010121093A3 (en) Humanized antibody compositions and methods for binding lysophosphatidic acid
WO2010136483A3 (en) Antigen-binding proteins
BR112012010591A2 (pt) "conjugado de moléculas, ácido nucleico e método pe produção de conjugado de móleculas"
WO2010127180A3 (en) Dc-stamp antibodies

Legal Events

Date Code Title Description
FG Grant or registration